Heidi M. Hagen

Heidi M. Hagen, MBA is Co-Founder of, and Advisor to, Vineti, Inc., a privately‑held company that develops and commercializes cloud‑based software platforms for ordering, manufacturing and delivering personalized medicines. Previously, Ms. Hagen served as interim Chief Commercial Officer at ZappRx, Inc. from January 2015 to June 2015. Ms. Hagen also served as Global Chief Operating Officer at Sotio LLC, a biotechnology company developing new therapies for the treatment of cancer and autoimmune diseases using its immunotherapy platform and proprietary cell‑based technologies, from March 2013 to April 2014. Before joining Sotio, Ms. Hagen served for ten years as Senior Vice President of Operations at Dendreon Corporation, where she was responsible for manufacturing and supply chain operations. Prior to joining Dendreon, Ms. Hagen spent nearly ten years at Immunex Corporation, where she held several positions in drug development and supply chain and operations management. Since June 2019, Ms. Hagen has served as a member of the boards of directors of Ziopharm Corporation, a publicly held company focused on developing the next generation of immuno-oncology gene and cell therapies, and Lykan Biosciences, a privately-held company focused on cell and gene manufacturing. Ms. Hagen earned a B.S. in cell and molecular biology, M.S. in bioengineering, and MBA from the University of Washington.